Owen Mumford's auto-injector technology will be jointly offered to biopharma firms to help their drug research programmes, with engineering and manufacturing support from Stevanato Group


The signing of the exclusive agreement between Stevanato Group and Owen Mumford. (Credit: Business Wire/ Stevanato Group)

Drug delivery solutions provider Stevanato Group has signed an exclusive agreement with medical device developer Owen Mumford to manufacture the latter’s Aidaptus auto-injector.

Under the agreement, Italy-based Stevanato Group will be the device’s sole manufacturing partner. The company will mould Aidaptus components and provide final and sub-assembly equipment, as well as pre-filled syringes.

Stevanato Group will assemble the components at its worldwide production facilities, while Owen Mumford will also assemble the components at its automated assembly centre of excellence in the UK.

Aidaptus is a two-step, single-use auto-injector with a flexible design that fits both 1mL and 2.25 mL prefilled glass syringes in the same base device.

It also has plunger sensing technology, which includes a self-adjusting plunger rod that adjusts to specific plunger positions and fills volumes in each syringe without the need for replace parts, said the firm.

The collaboration is said to add value to customers and simplify the production of the device.

Owen Mumford director Adam Mumford said: “Aidaptus will help patients to self-administer their individual therapies using a simple and easy to use the device.

“At the same time, this auto-injector can help reduce complexity, minimize supply chain risk and simplify final assembly for pharmaceutical and biotechnology companies, thanks to its ability to adapt to different viscosity, syringe sizes and fill volumes.

“Often during development or life-cycle management of injectable drug products, changes in these parameters can occur. Now for the first time, the device does not have to be changed as well.”

Stevanato Group chief business officer Mauro Stocchi said: “We believe this agreement is an important step in enhancing and growing the opportunities in our drug delivery systems portfolio as we broaden our capabilities in this key market.

“As we are constantly working with our customers to satisfy their needs, we continue to experience an increase in demand for auto-injectors.

“With this agreement, we will exploit the full breadth of Stevanato Group integrated capabilities being able to offer device manufacturing, assembly equipment, together with pre-fillable syringes and inspection systems.”